1036 related articles for article (PubMed ID: 28784313)
1. PCSK9 inhibition in the management of familial hypercholesterolemia.
Ogura M
J Cardiol; 2018 Jan; 71(1):1-7. PubMed ID: 28784313
[TBL] [Abstract][Full Text] [Related]
2. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
3. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Žák P
Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
5. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
Polychronopoulos G; Tziomalos K
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1375-1381. PubMed ID: 28884604
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.
El Khoury P; Elbitar S; Ghaleb Y; Khalil YA; Varret M; Boileau C; Abifadel M
Curr Atheroscler Rep; 2017 Oct; 19(12):49. PubMed ID: 29038906
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
[TBL] [Abstract][Full Text] [Related]
8. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
Agabiti Rosei E; Salvetti M
High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
[TBL] [Abstract][Full Text] [Related]
9. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
10. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
[TBL] [Abstract][Full Text] [Related]
11. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
12. PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option.
Pokrywka GS
Postgrad Med; 2018 Apr; 130(3):287-298. PubMed ID: 29411675
[TBL] [Abstract][Full Text] [Related]
13. [PCSK9 - "missing link" in familial hypercholesterolemia : New therapeutic options in hypercholesterolemia and coronary artery disease].
Thiery J; Burkhardt R
Herz; 2016 Jun; 41(4):281-9. PubMed ID: 27215417
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies.
Patel RS; Scopelliti EM; Savelloni J
Pharmacotherapy; 2015 Dec; 35(12):1189-203. PubMed ID: 26684558
[TBL] [Abstract][Full Text] [Related]
15. PCSK9 in cholesterol metabolism: from bench to bedside.
Reiss AB; Shah N; Muhieddine D; Zhen J; Yudkevich J; Kasselman LJ; DeLeon J
Clin Sci (Lond); 2018 Jun; 132(11):1135-1153. PubMed ID: 29895529
[TBL] [Abstract][Full Text] [Related]
16. Role of PCSK9 Inhibitors in High Risk Patients with Dyslipidemia: Focus on Familial Hypercholesterolemia.
Papademetriou V; Stavropoulos K; Papadopoulos C; Koutsampasopoulos K; Dimitriadis K; Tsioufis K
Curr Pharm Des; 2018; 24(31):3647-3653. PubMed ID: 30317985
[TBL] [Abstract][Full Text] [Related]
17. Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors.
Razek O; Cermakova L; Armani H; Lee T; Francis GA; Mancini GBJ; Frohlich J; Brunham LR
Can J Cardiol; 2018 Aug; 34(8):1004-1009. PubMed ID: 30056842
[TBL] [Abstract][Full Text] [Related]
18. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the pharmacological management of hypercholesterolaemia.
Ajufo E; Rader DJ
Lancet Diabetes Endocrinol; 2016 May; 4(5):436-46. PubMed ID: 27012540
[TBL] [Abstract][Full Text] [Related]
20. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
